MBOT Microbot Medical Inc

Edison Investment Research - StemCells - Ready to advance into Phase II 

StemCells made important progress in Q214 with the completion of enrolment in Phase I/II trials for age-related macular degeneration (AMD) and spinal cord injury (SCI), and released promising interim results in dry AMD. Full results are expected mid-2015. Phase II trials with its HuCNS-SC cells for both indications will be initiated during H214. Additionally, the company completed a $20m capital raise in July, which could provide funding through 2015.

StemCells, Inc. is applying its expertise in stem cell biology to discover, develop and commercialise stem cell-based therapeutics. It is currently developing HuCNS-SC human neural stem cells for spinal cord injury (SCI), Pelizaeus-Merzbacher Disease (PMD) and age-related macular degeneration (AMD). Preclinical programmes include those for Alzheimer's disease and stroke.

Follow the link to view the full report: http://www.edisoninvestmentresearch.com/research/report/stemcells2

Click here to view all of Edison Investment Research's published reports.